AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Jul 2014 03:30 PM
RNS
Total Voting Rights
01 Jul 2014 12:00 PM
RNS
Director/PDMR Shareholding
26 Jun 2014 02:00 PM
RNS
Director/PDMR Shareholding
26 Jun 2014 07:00 AM
RNS
FDA Advisory Committee votes on olaparib
24 Jun 2014 05:30 PM
RNS
Publication of Prospectus
18 Jun 2014 11:00 AM
RNS
Holding(s) in Company
18 Jun 2014 10:00 AM
RNS
Director/PDMR Shareholding
18 Jun 2014 10:00 AM
RNS
Director/PDMR Shareholding
13 Jun 2014 03:00 PM
RNS
Clarification of AXA shareholding in AstraZeneca
13 Jun 2014 07:00 AM
RNS
FDA AdCom recommends no CV trial for PAMORA class
12 Jun 2014 07:00 AM
RNS
ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001
11 Jun 2014 07:00 AM
RNS
AZ TO PRESENT NEW DATA AT ADA
03 Jun 2014 02:30 PM
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO
03 Jun 2014 07:00 AM
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO
02 Jun 2014 02:00 PM
RNS
Blocklisting Interim Review
02 Jun 2014 01:30 PM
RNS
Total Voting Rights
27 May 2014 04:14 PM
BZW
Form 8.3 - Astrazeneca Plc
27 May 2014 03:07 PM
BZW
Form 8.3 - AstraZeneca Plc
27 May 2014 07:00 AM
RNS
STATEMENT REGARDING PFIZER WITHDRAWAL
23 May 2014 03:16 PM
BZW
Form 8.3 - Astrazenica Plc
23 May 2014 03:13 PM
BZW
Form 8.3 - AstraZeneca Plc
23 May 2014 01:45 PM
BZW
Form 8.3 - Astrazeneca Plc
23 May 2014 01:43 PM
BZW
Form 8.3 - AstraZeneca PLC
23 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
22 May 2014 03:22 PM
BZW
Form 8.3 - AstraZeneca Plc
22 May 2014 03:01 PM
BZW
Form 8.3 - AstraZeneca Plc
22 May 2014 02:15 PM
BZW
Form 8.3 - AstraZeneca PLC
22 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
22 May 2014 10:56 AM
BZW
Form 8.3 - Astrazeneca Plc
21 May 2014 02:59 PM
BZW
Form 8.3 - Astrazenica Plc
21 May 2014 02:48 PM
BZW
Form 8.3 - AstraZeneca Plc
21 May 2014 12:38 PM
BZW
Form 8.3 - AstraZeneca PLC
21 May 2014 12:34 PM
BZW
Form 8.3 - Astrazeneca Plc
21 May 2014 11:29 AM
RNS
Rule 2.10 Announcement
20 May 2014 06:17 PM
RNS
CLARIFICATION REGARDING PFIZER STATEMENT
20 May 2014 04:32 PM
BZW
Form 8.3 - Astrazenica Plc
20 May 2014 02:27 PM
BZW
Form 8.3 - AstraZeneca Plc
20 May 2014 01:51 PM
BZW
Form 8.3 - AstraZeneca PLC
20 May 2014 11:53 AM
BZW
Form 8.3 - Astrazeneca Plc
20 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
19 May 2014 03:31 PM
BZW
Form 8.3 - AstraZeneca Plc
19 May 2014 03:26 PM
BZW
Form 8.3 - Astrazenica Plc
19 May 2014 01:13 PM
BZW
Form 8.3 - AstraZeneca PLC
19 May 2014 11:18 AM
BZW
Form 8.3 - Astrazeneca Plc
19 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
19 May 2014 07:08 AM
RNS
ASTRAZENECA BOARD REJECTS PFIZER'S FINAL PROPOSAL
16 May 2014 03:14 PM
BZW
Form 8.3 - AstraZeneca Plc
16 May 2014 02:40 PM
BZW
Form 8.3 - AstraZeneca Plc
16 May 2014 01:54 PM
BZW
Form 8.3 - AstraZeneca PLC
16 May 2014 12:59 PM
BZW
Form 8.3 - Astrazeneca Plc
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100